Rasagiline Mesylate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318653

CAS#: 161735-79-1 (mesylate)

Description: Rasagiline Mesylate is a selective irreversible MAO-B inhibitor. It displays anti-Parkinsonian activity, exhibits neuroprotective and antiapoptotic activity against several neurotoxins in cell culture.

Chemical Structure

img
Rasagiline Mesylate
CAS# 161735-79-1 (mesylate)
Instruction

Theoretical Analysis

Hodoodo Cat#: H318653
Name: Rasagiline Mesylate
CAS#: 161735-79-1 (mesylate)
Chemical Formula: C13H17NO3S
Exact Mass: 0.00
Molecular Weight: 267.340
Elemental Analysis: C, 58.40; H, 6.41; N, 5.24; O, 17.95; S, 11.99

Price and Availability

Size Price Availability Quantity
100mg USD 650 2 Weeks
200mg USD 950 2 Weeks
500mg USD 1450 2 Weeks
1g USD 2450 2 Weeks
2g USD 3950 2 Weeks
5g USD 6450 2 Weeks
Bulk inquiry

Related CAS #: 136236-51-6 (free base)   161735-79-1 (mesylate)   136236-52-7 (tartrate)    

Synonym: Rasagiline Mesylate; Azilect; TVP-1012; Rasagiline mesilate; Agilect; TVP-1022; TVP1022; TVP-101; AGN 1135; AGN-1135; Azilect; N-2-propynyl-1-indanamine N-propargyl-1-aminoindan mesylate; rasagiline; rasagiline hydrochloride; TVP 101; TVP 1022;

IUPAC/Chemical Name: N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine methanesulfonate

InChi Key: JDBJJCWRXSVHOQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)

SMILES Code: CS(=O)(=O)O.C#CCNC1CCC2=CC=CC=C12

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 267.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pingili R, Vemulapalli S, Mullapudi SS, Nuthakki S, Pendyala S, Kilaru N.
Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and
rasagiline mesylate in wistar rats. Drug Dev Ind Pharm. 2015 Nov 30:1-8. [Epub
ahead of print] PubMed PMID: 26530401.


2: Müller T. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate
for Parkinson's disease. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1423-32.
doi: 10.1517/17425255.2014.943182. Epub 2014 Sep 6. Review. PubMed PMID:
25196265.


3: Viveksarathi K, Kannan K. Effect of the moist-heat sterilization on fabricated
nanoscale solid lipid particles containing rasagiline mesylate. Int J Pharm
Investig. 2015 Apr-Jun;5(2):87-91. doi: 10.4103/2230-973X.153383. PubMed PMID:
25838993; PubMed Central PMCID: PMC4381391.


4: Kunasekaran V, Krishnamoorthy K. Multi criteria decision making to select the
best method for the preparation of solid lipid nanoparticles of rasagiline
mesylate using analytic hierarchy process. J Adv Pharm Technol Res. 2014
Jul;5(3):115-21. doi: 10.4103/2231-4040.137410. PubMed PMID: 25126532; PubMed
Central PMCID: PMC4131401.


5: Ravi PR, Aditya N, Patil S, Cherian L. Nasal in-situ gels for delivery of
rasagiline mesylate: improvement in bioavailability and brain localization. Drug
Deliv. 2015;22(7):903-10. doi: 10.3109/10717544.2013.860501. Epub 2013 Nov 29.
PubMed PMID: 24286183.


6: Genina N, Janßen EM, Breitenbach A, Breitkreutz J, Sandler N. Evaluation of
different substrates for inkjet printing of rasagiline mesylate. Eur J Pharm
Biopharm. 2013 Nov;85(3 Pt B):1075-83. doi: 10.1016/j.ejpb.2013.03.017. Epub 2013
Apr 4. PubMed PMID: 23563101.


7: Shelke PG, Chandewar AV. Study of stress degradation behavior of rasagiline
mesylate under hydrolytic conditions by high performance liquid chromatography.
Drug Res (Stuttg). 2014 Apr;64(4):182-5. doi: 10.1055/s-0033-1355332. Epub 2013
Sep 18. PubMed PMID: 24048951.


8: Reddy PS, Babu KS, Kumar N. A validated normal phase LC method for
enantiomeric separation of rasagiline mesylate and its (S)-enantiomer on
cellulose derivative-based chiral stationary phase. Chirality. 2013
Jun;25(6):324-7. doi: 10.1002/chir.22150. Epub 2013 May 9. PubMed PMID: 23658136.


9: Reddy PS, Sudhakar Babu K, Kumar N. Development and validation of a
stability-indicating RP-HPLC method for the simultaneous estimation of process
related impurities and degradation products of rasagiline mesylate in
pharmaceutical formulation. J Chromatogr Sci. 2013 Mar;51(3):242-9. doi:
10.1093/chromsci/bms134. Epub 2012 Sep 17. PubMed PMID: 22988002.


10: Ravi PR, Aditya N, Cherian L, Patil S. LC method for determination of
rasagiline mesylate in different plasma matrices and its application to oral
pharmacokinetic study in rabbits. J Chromatogr Sci. 2013 Jan;51(1):1-7. doi:
10.1093/chromsci/bms096. Epub 2012 Jun 11. PubMed PMID: 22689899.


11: Meier-Davis SR, Dines K, Arjmand FM, Hamlin R, Huang B, Wen J, Christianson
C, Shudo J, Nagata T. Comparison of oral and transdermal administration of
rasagiline mesylate on human melanoma tumor growth in vivo. Cutan Ocul Toxicol.
2012 Dec;31(4):312-7. doi: 10.3109/15569527.2012.676119. Epub 2012 Apr 20. PubMed
PMID: 22515841.


12: Fernández M, Barcia E, Fernández-Carballido A, Garcia L, Slowing K, Negro S.
Controlled release of rasagiline mesylate promotes neuroprotection in a
rotenone-induced advanced model of Parkinson's disease. Int J Pharm. 2012 Nov
15;438(1-2):266-78. doi: 10.1016/j.ijpharm.2012.09.024. Epub 2012 Sep 15. PubMed
PMID: 22985602.


13: Fernández M, Barcia E, Negro S. Development and validation of a reverse phase
liquid chromatography method for the quantification of rasagiline mesylate in
biodegradable PLGA microspheres. J Pharm Biomed Anal. 2009 Jul 12;49(5):1185-91.
doi: 10.1016/j.jpba.2009.02.031. Epub 2009 Mar 13. PubMed PMID: 19356876.


14: Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R,
Djaldetti R, Klein C, Berecz G; Rasagiline Study Group. Rasagiline mesylate, a
new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind
study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000
Nov-Dec;23(6):324-30. PubMed PMID: 11575866.


15: Hussar DA. New drugs: rasagiline mesylate, conivaptan hydrochloride, and
sunitinib malate. J Am Pharm Assoc (2003). 2006 Sep-Oct;46(5):650-5. PubMed PMID:
17036654.